Patents by Inventor Kenneth David Reginald Setchell
Kenneth David Reginald Setchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9408824Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: GrantFiled: March 5, 2014Date of Patent: August 9, 2016Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITEDInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Patent number: 9173866Abstract: A composition for use in making commercial food and skin products comprising R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The R-equol enantiomer can be produced by chiral-phase column separation from a racemic mixture of equol.Type: GrantFiled: July 24, 2003Date of Patent: November 3, 2015Assignees: Children's Hospital Medical Center, Australian Health & Nutrition Association LimitedInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Patent number: 9018247Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: GrantFiled: June 1, 2011Date of Patent: April 28, 2015Assignees: Children's Hospital Medical Center, Australian Health & Nutrition Association LimitedInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Publication number: 20150038570Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: ApplicationFiled: March 5, 2014Publication date: February 5, 2015Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITEDInventors: Kenneth David Reginald SETCHELL, Sidney John COLE
-
Publication number: 20140227392Abstract: A beer obtained from the fermentation process of cereals and/or legumes is described. Said beer is characterized in that it comprises isoflavones aglycons that are biologically active forms of isoflavones.Type: ApplicationFiled: September 2, 2011Publication date: August 14, 2014Applicant: FARCHIONI OLII - S.P.A.Inventors: Carlo Clerici, Kenneth David Reginald Setchell
-
Publication number: 20140135387Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.Type: ApplicationFiled: May 28, 2013Publication date: May 15, 2014Applicants: Brigham Young University, Children's Hospital Center, Colorado State University Research FoundationInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Patent number: 8716497Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: September 10, 2012Date of Patent: May 6, 2014Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Patent number: 8668914Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.Type: GrantFiled: July 31, 2009Date of Patent: March 11, 2014Assignees: Brigham Young University, Colorado State University Research Foundation, Children's Hospital Medical CenterInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Publication number: 20140039046Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: ApplicationFiled: August 28, 2013Publication date: February 6, 2014Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITEDInventors: Kenneth David Reginald SETCHELL, Sidney John COLE
-
Patent number: 8580846Abstract: The invention is directed to a method of preventing or ameliorating a neuropsychiatric or neurodegenerative disease or disorder in a subject. The method includes administering a composition comprising equol in an amount sufficient to prevent or ameliorate the neuropsychiatric or neurodegenerative disease or disorder. The equol may be a racemic mixture of R-equol and S-equol. The equol may be enantiomerically enriched with R-equol or enantiomerically enriched with S-equol.Type: GrantFiled: August 18, 2006Date of Patent: November 12, 2013Assignees: Brigham Young University, Children's Hospital Medical Center, Colorado State University Research FoundationInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Patent number: 8450364Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.Type: GrantFiled: April 9, 2012Date of Patent: May 28, 2013Assignees: Brigham Young University, Colorado State University Research Foundation, Children's Hospital Medical Center of Cincinnati, OhioInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Publication number: 20130116450Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: ApplicationFiled: September 10, 2012Publication date: May 9, 2013Applicants: GIRINDUS AMERICA, INC., CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Kenneth David Reginald SETCHELL, Victor Dmitrievich Sorokin
-
Publication number: 20120264821Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.Type: ApplicationFiled: April 9, 2012Publication date: October 18, 2012Inventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Patent number: 8263790Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: June 1, 2011Date of Patent: September 11, 2012Assignees: Children's Hospital Medical Center, Girindus America, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
-
Patent number: 8153684Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.Type: GrantFiled: October 2, 2009Date of Patent: April 10, 2012Assignees: Colorado State University Research Foundation, Brigham Young University Technology Transfer Office, Children's Hospital Medical Center of Cincinnati, OhioInventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
-
Publication number: 20120040921Abstract: A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: ApplicationFiled: October 26, 2011Publication date: February 16, 2012Applicant: AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITEDInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Publication number: 20120004189Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: ApplicationFiled: June 1, 2011Publication date: January 5, 2012Applicants: AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED, CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Kenneth David Reginald SETCHELL, Sidney John Cole
-
Publication number: 20120004427Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: ApplicationFiled: June 1, 2011Publication date: January 5, 2012Applicants: GIRINDUS AMERICA, INC., CHILDREN'S HOSPITAL MEDICAL CENTERInventors: Kenneth David Reginald SETCHELL, Victor Dmitrievich Sorokin
-
Patent number: 8048913Abstract: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.Type: GrantFiled: September 14, 2009Date of Patent: November 1, 2011Assignees: Australian Health & Nutrition Assoc. Ltd., Children's Hospital Medical CenterInventors: Kenneth David Reginald Setchell, Sidney John Cole
-
Patent number: 7960573Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.Type: GrantFiled: May 4, 2009Date of Patent: June 14, 2011Assignees: Children's Hospital Medical Center, Girindus America, Inc.Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin